Analyst firms · Wolfe Research · CORT
Wolfe Research CORT price target and rating history
Corcept Therapeutics Incorporated (CORT) · Health Care
Wolfe Research rates Corcept Therapeutics Incorporated (CORT) Underperform with a $50 price target, as of its latest action on Jul 27, 2026. It has published 4 rating actions on CORT since November 2025, including 1 upgrade and 2 downgrades. Across 3 firms with a CORT price target in the last 12 months, the median target is $72. Wolfe Research's $50 is 31% below that.
- Current rating
- Underperform
- Price target
- $50
- Median target, all firms
- $72
- Actions on CORT
- 4
Wolfe Research price target on CORT
Every Wolfe Research rating on CORT
- Jul 27, 2026
- Mar 26, 2026
- Dec 31, 2025
- Nov 18, 2025
How other firms rate CORT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Truist Securities | Buy | $164 | Aug 18, 2026 |
| Wolfe Research | Underperform | $50 | Jul 27, 2026 |
| UBS | Buy | $72 | May 13, 2026 |
Questions about Wolfe Research and CORT
- What is Wolfe Research's price target for CORT?
- Wolfe Research's latest stated price target for Corcept Therapeutics Incorporated (CORT) is $50, from its action on Jul 27, 2026.
- What is Wolfe Research's rating on CORT?
- Wolfe Research rates CORT Underperform, a bearish rating, as of Jul 27, 2026.
- When did Wolfe Research last change its view on CORT?
- On Jul 27, 2026, Wolfe Research downgrades to Underperform from Peer Perform, price target $50.
- How does Wolfe Research's CORT target compare with other analysts?
- Across 3 firms with a CORT price target in the last 12 months, the median target is $72. Wolfe Research's $50 is 31% below that.
More CORT rating histories
All Wolfe Research ratingsCORT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.